<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137888">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932281</url>
  </required_header>
  <id_info>
    <org_study_id>1300304</org_study_id>
    <nct_id>NCT01932281</nct_id>
  </id_info>
  <brief_title>SierraSil as an Ergogenic Aid to Performance in Athletes</brief_title>
  <official_title>SierraSil as an Ergogenic Aid to Performance in Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether supplementation with SierraSil can improve
      anaerobic power and reduce muscle fatigue in a group of well-trained athletes.

      A secondary purpose is to examine the effect of SierraSil on the severity of delayed onset
      muscle soreness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, crossover, pilot study that will examine the effect of SierraSil
      supplementation on the determinants of human performance. Anaerobic capacity, muscle
      fatigue, the severity of delayed onset muscle soreness (DOMS) and markers of inflammation
      will be measured before and after 3 weeks of supplementation with SierraSil or placebo.
      There will be a 3 week washout period prior to the crossover to ensure SierraSil
      supplementation has no residual effect.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in total anaerobic capacity</measure>
    <time_frame>change from baseline at 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Muscle Power</condition>
  <condition>Muscle Fatigue</condition>
  <arm_group>
    <arm_group_label>SierraSil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SierraSil</intervention_name>
    <description>SierraSil is a natural, mineral supplement currently used to improve joint health and function.</description>
    <arm_group_label>SierraSil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic SierraSil 667 mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no contraindications to strenuous exercise

        Exclusion Criteria:

          -  muscle or joint injury

          -  taking any form of anti-inflammatory or pain medication

          -  females due to the variability that might be introduced due to the phases of the
             menstrual cycle
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald C. McKenzie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana K Jespersen</last_name>
    <phone>604 822 6755</phone>
    <email>diana.jespersen@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana K Jespersen</last_name>
      <phone>604 822 6755</phone>
      <email>diana.jespersen@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Donald C. McKenzie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscle power</keyword>
  <keyword>muscle fatigue</keyword>
  <keyword>SierraSil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
